These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33821748)

  • 1. Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence.
    Cortell Fuster C; Martínez Gómez MA; Cercós Lleti AC; Climente Martí M
    J Dermatolog Treat; 2022 Jun; 33(4):1804-1810. PubMed ID: 33821748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Topical Sirolimus for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex.
    Dao DD; Pixley JN; Akkurt ZM; Feldman SR
    Ann Pharmacother; 2024 Apr; 58(4):428-433. PubMed ID: 37386842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Topical Rapamycin in Patients With Facial Angiofibromas Secondary to Tuberous Sclerosis Complex: The TREATMENT Randomized Clinical Trial.
    Koenig MK; Bell CS; Hebert AA; Roberson J; Samuels JA; Slopis JM; Tate P; Northrup H;
    JAMA Dermatol; 2018 Jul; 154(7):773-780. PubMed ID: 29800048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis complex.
    Balestri R; Neri I; Patrizi A; Angileri L; Ricci L; Magnano M
    J Eur Acad Dermatol Venereol; 2015 Jan; 29(1):14-20. PubMed ID: 25174683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical everolimus for facial angiofibromas in the tuberous sclerosis complex. A first case report.
    Dill PE; De Bernardis G; Weber P; Lösch U
    Pediatr Neurol; 2014 Jul; 51(1):109-13. PubMed ID: 24810875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A survey of patients with facial angiofibromas associated with tuberous sclerosis complex: Short-, medium- and long-term efficacy and safety of topical rapamycin.
    Sigg N; Fouquet J; Morin D; Farges D; Vrignaud S; Martin L
    Ann Dermatol Venereol; 2023 Dec; 150(4):270-273. PubMed ID: 37821253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of current data on the use of topical mTOR inhibitors in the treatment of facial angiofibromas in tuberous sclerosis complex-An update.
    Balestri R; Rizzoli L; Pedrolli A; Urru SAM; Rech G; Neri I; Girardelli CR; Magnano M
    J Eur Acad Dermatol Venereol; 2023 Mar; 37(3):474-487. PubMed ID: 36300771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex: a double-blind, randomized, controlled trial to evaluate the safety and efficacy of topically applied rapamycin.
    Koenig MK; Hebert AA; Roberson J; Samuels J; Slopis J; Woerner A; Northrup H
    Drugs R D; 2012 Sep; 12(3):121-6. PubMed ID: 22934754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex: A Randomized Clinical Trial.
    Wataya-Kaneda M; Ohno Y; Fujita Y; Yokozeki H; Niizeki H; Ogai M; Fukai K; Nagai H; Yoshida Y; Hamada I; Hio T; Shimizu K; Murota H
    JAMA Dermatol; 2018 Jul; 154(7):781-788. PubMed ID: 29800026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effects of Topical 0.2% Sirolimus for Angiofibromas in Adults and Pediatric Patients with Tuberous Sclerosis Complex.
    Lee YI; Lee JH; Kim DY; Chung KY; Shin JU
    Dermatology; 2018; 234(1-2):13-22. PubMed ID: 29925060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of topical rapamycin-calcitriol for facial angiofibromas in patients with tuberous sclerosis complex: a prospective, double-blind, randomized clinical trial.
    Chen PL; Hong JB; Shen LJ; Chen YT; Wang SJ; Liao YH
    Br J Dermatol; 2020 Oct; 183(4):655-663. PubMed ID: 32064596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Topical Sirolimus Therapy for Facial Angiofibromas in the Tuberous Sclerosis Complex : A Randomized Clinical Trial.
    Wataya-Kaneda M; Nakamura A; Tanaka M; Hayashi M; Matsumoto S; Yamamoto K; Katayama I
    JAMA Dermatol; 2017 Jan; 153(1):39-48. PubMed ID: 27837201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First left-right comparative study of topical rapamycin vs. vehicle for facial angiofibromas in patients with tuberous sclerosis complex.
    Tanaka M; Wataya-Kaneda M; Nakamura A; Matsumoto S; Katayama I
    Br J Dermatol; 2013 Dec; 169(6):1314-8. PubMed ID: 23909960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topical rapamycin: a novel approach to facial angiofibromas in tuberous sclerosis.
    Haemel AK; O'Brian AL; Teng JM
    Arch Dermatol; 2010 Jul; 146(7):715-8. PubMed ID: 20644030
    [No Abstract]   [Full Text] [Related]  

  • 15. [Facial angiofibromas associated to tuberous sclerosis treated with topical sirolimus].
    Tiedemann Svendsen M; Bygum A; Hansen LK; Broesby-Olsen S
    Ugeskr Laeger; 2013 Oct; 175(43):2569-70. PubMed ID: 24629155
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained clinical effectiveness and favorable safety profile of topical sirolimus for tuberous sclerosis - associated facial angiofibroma.
    Salido R; Garnacho-Saucedo G; Cuevas-Asencio I; Ruano J; Galán-Gutierrez M; Vélez A; Moreno-Giménez JC
    J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1315-8. PubMed ID: 21834948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical rapamycin for angiofibromas in paediatric patients with tuberous sclerosis: follow up of a pilot study and promising future directions.
    Tu J; Foster RS; Bint LJ; Halbert AR
    Australas J Dermatol; 2014 Feb; 55(1):63-9. PubMed ID: 24359523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel topical rapamycin cream for the treatment of facial angiofibromas in tuberous sclerosis complex.
    Wheless JW; Almoazen H
    J Child Neurol; 2013 Jul; 28(7):933-6. PubMed ID: 23680945
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberous Sclerosis Complex in 29 Children: Clinical and Genetic Analysis and Facial Angiofibroma Responses to Topical Sirolimus.
    Wang S; Liu Y; Wei J; Zhang J; Wang Z; Xu Z
    Pediatr Dermatol; 2017 Sep; 34(5):572-577. PubMed ID: 28771801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel rapamycin cream formulation improves facial angiofibromas associated with tuberous sclerosis complex: a double-blind randomized placebo-controlled trial.
    Aitken P; Stanescu I; Boddington L; Mahon C; Fogarasi A; Liao YH; Ivars M; Moreno-Artero E; Trauner D; DeRoos ST; Jancic J; Nikolic M; Balážová P; Price HN; Hadzsiev K; Riney K; Stapleton S; Tollefson MM; Bauer D; Pinková B; Atkinson H
    Br J Dermatol; 2023 Oct; 189(5):520-530. PubMed ID: 37463422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.